These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 8174107)

  • 1. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
    Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
    Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of p53 in Wilms' tumors.
    Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
    Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
    Bardeesy N; Beckwith JB; Pelletier J
    Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
    Lahoti C; Thorner P; Malkin D; Yeger H
    Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
    Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
    Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors.
    el Bahtimi R; Hazen-Martin DJ; Re GG; Willingham MC; Garvin AJ
    Mod Pathol; 1996 Mar; 9(3):238-44. PubMed ID: 8685221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 expression in Wilms' tumor: a possible role as prognostic factor.
    Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G
    Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
    Roberts DJ; Haber D; Sklar J; Crum CP
    Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
    Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
    Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
    Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.
    Haber DA; Buckler AJ
    New Biol; 1992 Feb; 4(2):97-106. PubMed ID: 1313285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A point mutation within exon 5 of the WT1 gene of a sporadic unilateral Wilms' tumor alters gene function.
    Guan LS; Liu JJ; Xu YH; Wang ZY
    Cancer Res; 1998 Sep; 58(18):4180-4. PubMed ID: 9751632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
    Pelletier J; Bruening W; Li FP; Haber DA; Glaser T; Housman DE
    Nature; 1991 Oct; 353(6343):431-4. PubMed ID: 1654525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
    Grubb GR; Yun K; Reeve AE; Eccles MR
    Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.